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Objective To examine the association between nondefect adverse
birth outcomes and in utero exposure to zidovudine (ZDV)-
containing regimens versus non-ZDV antiretroviral (ARV)
regimens.
Design Analysis of prospectively-collected data.
Setting Global.
Population HIV-infected pregnant women prenatally exposed to
antiretrovirals.
Methods Estimation of prevalence of and risk for nondefect
adverse birth outcomes among HIV-infected women.
Main outcome measures Prevalence of and risk for nondefect
adverse birth outcomes.
Results Among 12 780 singleton birth outcomes with in utero
ZDV exposure, 96.1% were live births; 3.9% were spontaneous
abortions, induced abortions or stillbirths. Among live births,
16.4% were low birthweight (LBW); 12.3% were premature.
Among 1904 outcomes with in utero exposure to non-ZDV ARV
regimens, 85.8% were live births; 14.2% were spontaneous
abortions, induced abortions or stillbirths. Among live births,
14.1% were LBW; 12.4% were premature. Relative risk
comparing exposure to ZDV-containing ARV regimens to non-
ZDV ARV regimens for spontaneous abortions was 0.18 (95%
confidence interval [95% CI] 0.14–0.22); induced abortions 0.28
(95% CI 0.22–0.36); stillbirths 0.76 (95% CI 0.51–1.12);
premature births 1.00 (95% CI 0.87–1.15) and LBW 1.17 (95%
CI 1.02–1.33).
Conclusion Prevalence of nondefect adverse birth outcomes is
lower among outcomes with in utero ZDV exposure versus in
utero non-ZDV ARV exposure. The risks for spontaneous and
induced abortions were no different for ZDV-containing regimens
versus non-ZDV ARV regimens. For premature births and
stillbirths, there was no significant difference in risk between the
two regimens. The risk of LBW was statistically significantly
higher among ZDV-containing regimens versus non-ZDV ARV
regimens.
Keywords Epidemiology HIV, pregnancy outcomes, zidovudine.
Tweetable abstract ZDV-containing regimens do not increase the
risk for nondefect adverse birth outcomes.
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Introduction
Zidovudine (ZDV) was the first antiretroviral (ARV) to be
approved for treatment of HIV/AIDS in the USA. WHO
guidelines for first-line regimens for HIV-positive pregnant
women include ZDV.1,2
The Antiretroviral Pregnancy Registry (APR) monitors
birth defects in pregnant women exposed to ARVs. Data
from the most recent APR interim report published in June
2014 indicate that the overall prevalence of birth defects
following first-trimester exposure to any ARV monitored
by the registry is 2.8 (95% confidence interval [95% CI]:
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2.5–3.3)3*. This proportion is not significantly higher than
those reported in the APR’s two population-based com-
parators, the Metropolitan Atlanta Congenital Defects Pro-
gram (the Centers for Disease Control and Prevention’s
birth defects surveillance system) with 2.72 per 100 live
births4 and the Texas Birth Defects Registry with a reported
rate of 4.17 per 100 live births.5 Among first-trimester
ZDV exposures, the APR reports no increase in the risk of
overall birth defects, nor in the risk of birth defects in the
cardiovascular and genitourinary systems.6 The prevalence
of birth defects among women with first-trimester ZDV
exposure is 3.2% (95% CI 2.7–3.8%).3 The complete APR
interim report is available online at http://www.apregistry.-
com/forms/interim_report.pdf.
The full prescribing information for ZDV in the USA
suggests that although no differences in pregnancy-related
adverse events between pregnant women with ZDV expo-
sure compared with those with placebo exposure have been
observed, animal studies have shown teratogenicity, result-
ing in a US Food and Drug Administration Pregnancy Cat-
egory C status. In this analysis, we examine the association
between adverse pregnancy outcomes other than birth
defects and the use of ZDV-containing regimens during
pregnancy, compared with non-ZDV ARV regimens.
Methods
This is a secondary analysis of data from the APR from 1
January 1989 through to 31 July 2013. The APR is
described in detail in a previous analysis.7 Briefly, the APR
is a pregnancy registry that monitors for early signal of
increased risk for birth defects following prenatal exposure
to ARVs. The majority of case reports are from the USA
and its territories (77.6%); the remaining reports are from
66 other countries.3
Pregnant women prenatally exposed to any ARV are
prospectively registered before the birth outcome being
known, and are followed through to the end of the preg-
nancy. Data on maternal risk factors and birth outcomes
are also collected. The APR has institutional review board
(IRB) approval from Western IRB, and was granted a
waiver from obtaining informed consent.
A birth outcome is defined at the time of delivery or
fetal loss, or when a defect detected on a prenatal test is
reported at enrolment. Although the APR also collects data
from clinical trials and retrospective studies, the primary
APR cohort is limited to prospectively registered women.
Only singleton births are included in the current analysis;
multiple births such as twin and triplet births are excluded
because of the increased risk of adverse outcomes associ-
ated with such pregnancies.8–10 We also compare in utero
ZDV exposure at any time during pregnancy to in utero
non-ZDV exposure, because drug exposure at any time
during pregnancy may be relevant for birth outcomes.
Gestational weeks are calculated starting from the first
day of the last menstrual period. If the date of the last
menstrual period is unknown, the estimated delivery date
is used. If gestational week is inconsistent with exposure
dates and/or the date of outcome (outside  1 week for
the first trimester, outside  2 weeks for the second and
third trimesters), a corrected estimated delivery date where
ultrasound data are available is used.
The following adverse birth outcomes other than birth
defects are included in our analyses: spontaneous and
induced abortions, stillbirths, premature births (<37 weeks
gestation), very premature births (<32 weeks gestation),
low birthweight (LBW; <2500 g) and very low birthweight
(VLBW; <1500 g). The APR defines spontaneous abortion
as death of a fetus or expulsion of the products of concep-
tion before 20 weeks gestation. A stillbirth is defined as the
death of a fetus occurring at 20 weeks of gestation or more,
or for situations in which the gestational age is unavailable,
a fetus weighing at least 500 g.
Statistical analysis
The prevalence of nondefect adverse birth outcomes was
estimated, and the relative risks and 95% CI comparing
outcomes with prenatal exposure to ZDV-containing regi-
mens versus exposure to non-ZDV ARV regimens were cal-
culated. Depending on whether the data analysed were
continuous or categorical, the independent t-test or Fisher’s
exact test was used to calculate P-values. Unknown or
missing values were excluded from the analysis. For sponta-
neous losses, induced abortions and stillbirths, prevalence
was estimated using the total number of pregnancies as the
denominator, with the 95% CI based on the Clopper–Pear-
son exact binomial method.11,12 For prematurity and LBW,
prevalence was estimated using the total number of live
singleton births as the denominator. Outcomes with birth
defects, and all outcomes with unknown gestational age or
unknown birthweight, were excluded. The 95% CI were
calculated using the Clopper–Pearson exact binomial
method. Relative risks were calculated comparing
*The APR Advisory Committee Consensus Statement3: In reviewing all
reported defects from the prospective registry, informed by clinical studies
and retrospective reports of antiretroviral exposure, the Registry finds no
apparent increases in frequency of specific defects with first-trimester expo-
sures and no pattern to suggest a common cause. The Registry notes mod-
est but statistically significant elevations of overall defect rates with
didanosine and nelfinavir compared with its population-based compara-
tors, the Metropolitan Atlanta Congenital Defects Program and Texas Birth
Defects Registry. While the Registry population exposed and monitored to
date is not sufficient to detect an increase in the risk of relatively rare
defects, these findings should provide some assurance when counselling
patients. However, potential limitations of registries such as this should be
recognised. The Registry is ongoing. Healthcare providers are encouraged
to report eligible patients to the Registry at www.APRegistry.com.
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ZDV-containing regimens to non-ZDV ARV regimens. The
95% CI for the relative risks were calculated using the nor-
mal asymptotic method. All analyses were performed using
SAS v9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Maternal demographics
Of the 14 950 pregnancies from prospectively registered
HIV-infected women for which outcome is known, 14 684
were singleton pregnancies, 262 were pregnancies with
twins and four were with triplets. Pregnancies with multi-
ple outcomes were excluded from all subsequent analyses.
Of the 14 684 singleton pregnancy outcomes, 12 780
were prenatally exposed to ZDV in any trimester; 1904 had
prenatal non-ZDV ARV exposure. Table 1 describes mater-
nal demographics for these two groups. We found no dif-
ference between groups in baseline CD4 counts; however,
women exposed to non-ZDV ARV combinations were
older. A higher proportion of Hispanic women were on
ZDV-containing regimens compared with non-ZDV ARV
regimens (Table 1). A listing of ZDV-containing regimens
and non-ZDV regimens is presented in Table 2.
Among the 12 780 singleton pregnancies with in utero
ZDV exposure, 96.1% were live births, and 3.9% were non-
defect adverse outcomes (spontaneous abortions 1.3%;
induced abortions 1.4%; stillbirths 1.2%). When restricted
to ZDV exposures in the first trimester, the prevalence of
spontaneous abortions increased to 3.7% and induced
abortions increased to 4.2%. Among live births, 16.4% had
LBW <2500 g, 2.1% had VLBW <1500 g, 12.3% were pre-
mature <37 weeks gestation, and 2.2% were very premature
<32 weeks gestation. Among 1904 outcomes with in utero
non-ZDV ARV regimen exposure, 85.8% were live births
and 14.2% resulted in nondefect adverse outcomes (sponta-
neous abortions 7.6%; induced abortions 5.1%; stillbirths
1.5%). When restricted to non-ZDV exposures in the first
trimester, the proportion of spontaneous abortions
increased to 9.6% and induced abortions increased to
6.4%. Among live births, 14.1% had LBW <2500 g, 1.9%
had VLBW <1500 g, 12.4% were premature <37 weeks
of gestation, and 2.1% were very premature <32 weeks of
Table 1. Maternal characteristics: singleton prospective pregnancies by ZDV exposure during pregnancy among HIV-infected women reported to
the APR through to 31 July 2013 with outcome
Characteristic Overall Regimens containing ZDV Regimens excluding ZDV P-value
Number of pregnancies 14 684 12 780 1904
Age (years)*
n 14 608 12 725 1883 <0.0001
Mean (SD) 28.2 (6.04) 27.9 (6.00) 30.0 (6.00)
Median (interquartile range) 28.0 (9.0) 28.0 (9.0) 30.0 (8.0)
Minimum – Maximum 13–55 13–55 14–48
Missing 76 (0.5%) 55 (0.4%) 21 (1.1%)
Race, n (%)**
White 2272 (15.5) 1969 (15.4) 303 (15.9) <0.0001
Black 8682 (59.1) 7506 (58.7) 1176 (61.8)
Hispanic 2915 (19.9) 2623 (20.5) 292 (15.3)
Asian 128 (0.9) 99 (0.8) 29 (1.5)
Other 402 (2.7) 333 (2.6) 69 (3.6)
Missing 285 (1.9) 250 (2.0) 35 (1.8)
CD4+ T-cell categories at start of pregnancy, n (%)**
≥500 ll 4561 (31.1) 3966 (31.0) 595 (31.3) 0.1071
200–499 ll 6583 (44.8) 5692 (44.5) 891 (46.8)
<200 ll 2407 (16.4) 2122 (16.6) 285 (15.0)
Unknown 77 (0.5) 64 (0.5) 13 (0.7)
N/A 24 (0.2) 13 (0.1) 11 (0.6)
Missing 1032 (7.0) 923 (7.2) 109 (5.7)
Country of reported origin, n (%)
USA 11 872 (80.8) 10 684 (83.6) 1188 (62.4) <0.0001
Other 2808 (19.1) 2093 (16.4) 715 (37.6)
Missing 4 (0.0) 3 (0.0) 1 (0.1)
Percentages are based on the number of pregnancies; pregnancies include 266 multiple gestation births (262 twin and four triplet).
*P-value is based on the independent t-test.
**P-value is based on the Fisher’s exact test (chi-square test for Race). Analysis does not include N/A, Unknown, or Missing values.
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gestation (Table 3). For APR overall, 8.6% of term deliver-
ies (≥37 weeks) were LBW <2500 g. Among pregnant
women with exposure to ZDV-containing regimens, 8.8%
of term deliveries (≥37 weeks) were LBW <2500 g; among
those with non-ZDV ARV exposure, 7.0% of term deliver-
ies were LBW.
The relative risks comparing exposure to ZDV-contain-
ing regimens with non-ZDV ARV regimens were 0.18
(95% CI 0.14–0.22; P < 0.0001) for spontaneous abortions;
0.28 (95% CI 0.22–0.36; P < 0.0001) for induced abortions;
0.76 (95% CI 0.51–1.12; P = 0.17) for stillbirths; 1.00 (95%
CI 0.87–1.15; P = 0.97) for preterm births; and 1.17 (95%
CI 1.02–1.33; P = 0.02) for LBW (Table 3).
The relative risks for spontaneous abortions and induced
abortions were significantly lower in the ZDV-exposed
group. The risks for stillbirths and preterm births were
similar between the two groups. The risk for LBW was sta-




A higher proportion of nondefect adverse pregnancy out-
comes was observed among infants with prenatal exposure
to non-ZDV ARV regimens, compared with those with
prenatal exposure to ZDV-containing regimens. For LBW,
a higher proportion was observed among infants with pre-
natal exposure to ZDV-containing regimens. However, sim-
ilar rates of prematurity were observed among both groups.
The risk for spontaneous and induced abortions was signif-
icantly lower among those with prenatal ZDV exposure,
compared with those with prenatal non-ZDV ARV expo-
sure, although this finding must be interpreted with cau-
tion as discussed below. The risk for LBW was significantly
higher among infants with in utero exposure to ZDV-con-
taining regimens. No significant difference was observed
between the two groups in risk of stillbirths and premature
births.
Strength and limitations
An advantage of this study is its large sample size. How-
ever, likely confounders such as disease status and severity,
which are not completely ascertained by the APR, and
unmeasured confounders, particularly non ARV-drug fac-
tors like concomitant drugs, illicit drug use, alcohol and
tobacco use, are not measured and controlled for in the
analyses. Unmeasured confounders may also include
health-related behaviours such as poor nutrition, which can
influence maternal body mass index. Adverse birth out-
comes other than birth defects are not the primary goal of
the APR or the reporting provider. This may have resulted
in possible underestimation of the birth outcomes analysed
in this study. Since LBW and VLBW are also outside the
scope of the APR, it was not possible to assess the morbid-
ity associated with these two variables. Very early preg-
nancy losses are difficult to capture under the voluntary
reporting nature of the registry, which leads to underesti-
mation of the losses. Reporting bias due to cultural or legal
constraints in countries where induced abortions are illegal
is also a possibility in this study and can result in the mis-
classification of these types of abortions as spontaneous
abortions. There is a lack of information regarding the tim-
ing of the initiation of antiretroviral therapy, as well as
indication for antiretroviral therapy; however, information
comparing exposure for the first time during the first tri-
mester versus in the second/third trimesters is available and
has been assessed in this analysis. Future research assessing
the risk associated with prenatal exposure to ARVs could
consider propensity scoring or use of instrumental vari-
ables, subject to availability of data, for more accurate esti-
mates.
Table 2. Regimens with and without ZDV by number of exposed
pregnancies reported to the APR through to 31 July 2013 with
outcome
Regimens containing ZDV Regimens excluding ZDV
≥1000 exposed pregnancies ≥1000 exposed pregnancies
ZDV n/a
3TC & NFV & ZDV
3TC & NVP & ZDV
3TC & LPV & RTV & ZDV
500–999 exposed pregnancies 500–999 exposed pregnancies
3TC & ZDV ATV & FTC & RTV & TDF
ABC & 3TC & ZDV
100–499 exposed pregnancies 100–499 exposed pregnancies
3TC & TDF & ZDV TDF
EFV & 3TC & ZDV FTC & TDF
IDV & 3TC & ZDV 3TC & NFV & d4T
3TC & NVP & d4T
EFV & 3TC & d4T
EFV & FTC & TDF
DRV & FTC & RTV & TDF
FTC & LPV & RTV & TDF
Regimens with <100 exposed pregnancies reported are not listed.
3TC, lamivudine; ABC, abacavir; ADV, adefovir dipivoxil; APV,
amprenavir; ATV, atazanavir sulphate; d4T, stavudine; ddC,
zalcitabine; ddI, didanosine; DLV, delavirdine mesylate; DRV,
darunavir; EFV, efavirenz; ETR, etravirine; ETV, entecavir; FOS,
fosamprenavir calcium; FTC, emtricitabine; IDV, indinavir; LdT,
telbivudine; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NFV,
nelfinavir; NVP, nevirapine; RAL, raltegravir; RPV, rilpivirine; RTV,
ritonavir; SQV, saquinavir mesylate or saquinavir;
TDF, tenofovir disporoxil fumatrate; TPV, tipranavir; and ZDV,
zidovudine. Occurrences of 3TC & ZDV may represent the
combination product.
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Interpretation
In a review of published literature, studies that have
examined the association between ZDV use in pregnancy
and adverse outcomes have typically looked at preterm
delivery as the outcome of interest.13–15 These studies
also compared the use of highly active antiretroviral
therapy (HAART) during pregnancy and ZDV
monotherapy. As most studies defined HAART based
upon the presence of either a protease inhibitor or non-
nucleoside reverse transcriptase inhibitor, and did not
specify the components of the nucleoside reverse tran-
scriptase inhibitor backbone of the regimen, it was often
not possible to determine the proportion of women
receiving ZDV for any particular analysis. In this study,
a wider range of adverse birth outcomes other than
birth defects are examined, as well as prematurity, and
ZDV-containing regimens are compared with non-ZDV
ARV regimens to better isolate the influence of ZDV use
during pregnancy on birth outcomes, so contributing to
the literature.
Data on the influence of ZDV use during pregnancy on
birth outcomes in published literature are conflicting. In
some studies that have compared HAART use to ZDV
monotherapy, an increased risk of preterm delivery among
HAART users has been reported.14,15 However, Tuomala
et al.16 reported on a combined analysis of five prospective
cohorts and two randomised controlled trials, and did
not find an effect of HAART on preterm delivery, in com-
parison to ZDV monotherapy (odds ratio 1.08, 95% CI
0.71–1.62). In this study, no significant difference in risk of
preterm delivery was observed between ZDV-containing
regimens and non-ZDV ARV regimens. Among studies that
examined LBW as an outcome, two African studies14,17
found an increased risk of LBW with HAART exposure
(either before pregnancy or antenatal exposure), whereas
three others16,18,19 (two in the USA, one in Latin America
and the Caribbean) found no effect. Data from this study
indicated an increased risk for LBW among pregnancy out-
comes with exposure to ZDV-containing regimens, com-
pared with non-ZDV ARV regimens.
Table 3. Prevalence and relative risk of non-defect adverse pregnancy outcomes: ZDV versus non-ZDV ARV exposed, reported to the
Antiretroviral Pregnancy Registry, prospective data through July 31, 2013





n (%) Prevalence (%)
(95% CI)
n (%) Prevalence (%)
(95% CI)
Live births 12 278 (96.1) – 1633 (85.8) – –
Spontaneous
Abortions*
171 (1.3) 1.34 (1.15, 1.55) 145 (7.6) 7.62 (6.46, 8.90) 0.18 (0.14, 0.22) <0.0001
Stillbirths* 147 (1.2) 1.15 (0.97, 1.35) 29 (1.5) 1.52 (1.02, 2.18) 0.76 (0.51, 1.12) 0.17
Induced abortions* 184 (1.4) 1.44 (1.24, 1.66) 97 (5.1) 5.09 (4.15, 6.18) 0.28 (0.22, 0.36) <0.0001
Total adverse birth
outcomes**
502 (3.9) – 271 (14.2) – – –
Birth weight*** n***** = 11044 – n***** = 1508 – – –
<2500 g 1811 (16.4) 16.40 (15.71, 17.10) 212 (14.1) 14.06 (12.34, 15.92) 1.17 (1.02, 1.33) 0.02
<1500 g 232 (2.1) – 28 (1.9) – – –
Unknown 881 – 89 – – –
Gestational
Age****
n****** = 11907 – n****** = 1587 – – –
<37 weeks 1467 (12.3) 12.32 (11.74, 12.92) 196 (12.4) 12.35 (10.77, 14.07) 1.00 (0.87, 1.15) 0.97
<32 weeks 257 (2.2) – 34 (2.1) – – –
Unknown 18 – 10 – – –
Percentages are based on the total outcomes in the respective analysis.
*Prevalence is based on the number of pregnancies. 95% CI is based on the exact binomial (Clopper-Pearson) method.
**Total adverse birth outcomes include still births, spontaneous or induced abortions, and exclude birth defects in live births
***Prevalence is based on the number of live singleton births – excludes cases with defects and cases with unknown birth weight. 95% CI is
based on the exact binomial (Clopper-Pearson) method.
****Prevalence is based on the number of live singleton births – excludes cases with defects and cases with unknown gestational age. 95% CI is
based on the exact binomial (Clopper-Pearson) method.
*****Excludes cases with unknown birth weight
******Excludes cases with unknown gestational age.
*******Relative Risk – Regimens Containing ZDV versus Regimens Excluding ZDV. The 95% CI is based on the normal asymptotic method. P-
value is based on the Fisher’s Exact test.
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In studies that have examined the relationship between
HAART or ZDV monotherapy use during pregnancy,
HAART was associated with a higher risk of still-
birth.14,20,21 Tuomala et al. reported a decreased risk of
stillbirth and prematurity associated with use of ZDV-con-
taining antiretroviral therapy in late pregnancy compared
with non-ZDV ARV therapy (odds ratio 0.06, 95% CI
0.02–0.18).21 In contrast, this study observed no significant
difference in risk of stillbirths associated with ZDV-con-
taining regimens compared with non-ZDV ARV regimens.
We also found that the risks for spontaneous abortions and
induced abortions were lower for ZDV-containing regimens
compared with non-ZDV ARV regimens. However, non-
ZDV regimens in this study were associated with older
maternal age, a variable highly correlated with pregnancy
loss rates, and this may explain some of the difference
noted here. Due to limitations in the data collection pro-
cess already described, although a statistically significant
lower risk for pregnancy loss was observed for ZDV-con-
taining regimens, it cannot be concluded that this regimen
is protective, but rather that compared to non-ZDV ARV
regimens, ZDV-containing regimens do not increase the
risk for spontaneous and induced abortions. Data on these
two outcomes in published literature are limited and fur-
ther research is recommended.
Conclusion
Data from this study show that the prevalence of adverse
birth outcomes other than birth defects is similar among
pregnant HIV-positive women prenatally exposed to ZDV
compared with those prenatally exposed to non-ZDV ARV
regimens. The risks for spontaneous abortions and induced
abortions were no different for exposure to ZDV-contain-
ing regimens compared with non-ZDV ARV regimens. For
prematurity and stillbirths, there was no significant differ-
ence in risk between the two regimens. However, the risk
of LBW was significantly higher among ZDV-containing
regimens compared with non-ZDV ARV regimens. Preg-
nant women must be carefully evaluated, and ZDV-con-
taining therapy prescribed only if the potential benefits to
the woman outweigh the potential risks to the fetus.
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